Drug Type Prophylactic vaccine, Conjugated vaccine |
Synonyms Next Gen PCV, Next-generation pneumococcal conjugate vaccine, PCV21 vaccine (Sanofi ) + [7] |
Target- |
Action stimulants |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Start Date22 May 2025 |
Sponsor / Collaborator |
Start Date28 Feb 2025 |
Sponsor / Collaborator |
Start Date27 Feb 2025 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Vaccination | Phase 3 | United States | 27 Feb 2025 | |
Vaccination | Phase 3 | Chile | 27 Feb 2025 | |
Vaccination | Phase 3 | Philippines | 27 Feb 2025 | |
Pneumococcal Infections | Phase 3 | South Korea | 18 Dec 2024 | |
Pneumococcal Infections | Phase 3 | Thailand | 18 Dec 2024 | |
Chickenpox | Phase 2 | United States | 22 May 2020 | |
Chickenpox | Phase 2 | Canada | 22 May 2020 | |
Chickenpox | Phase 2 | Honduras | 22 May 2020 | |
Chickenpox | Phase 2 | Puerto Rico | 22 May 2020 | |
Diphtheria | Phase 2 | United States | 22 May 2020 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 2 | 852 | (Stage I: Group 1 SP0202-IIb) | zxhgtznbpz = ppxwzvjfnh gkhclgwsvr (hhdhhtwldq, xikzgxsqhu - nedylakpkm) View more | - | 12 Nov 2024 | ||
(Stage I: Group 2 SP0202-VI) | zxhgtznbpz = kpzypioiwf gkhclgwsvr (hhdhhtwldq, flixbiwmpe - pmeshikiap) View more | ||||||
Phase 2 | 750 | (Group 1: SP0202-IIb) | rnsufgiiih(uwrwfssfzb) = ncrbsugvkf mgotblwihv (tmmmhthqji, nwjiptrqlm - dytnnjxufe) View more | - | 27 Aug 2024 | ||
(Group 2: SP0202-VI) | rnsufgiiih(uwrwfssfzb) = bndtxopgqp mgotblwihv (tmmmhthqji, zgapyxxwuu - ikmebmccjz) View more |